Xantos Biomedicine AG, NascaCell and PSF biotech collaborate on cancer drug discovery project
Xantos Biomedicine AG announced a collaboration with NascaCell IP GmbH and PSF biotech AG. The consortium is set to identify and develop new drugs for the inhibition of tumour angiogenesis, a process by which the growth of blood cells from surrounding tissue into a tumor is induced by a protein released from tumor cells.
The collaboration, using an aptamer-based approach, will integrate the innovative technology platforms of the three companies, combining Xantos' target discovery expertise and small molecule screening technology, PSF Biotech's protein production and crystallisation capabilities and NascaCell's aptamer technology for target validation and drug discovery. By combining the expertise of the three partners, the consortium called PADDION aims to develop new drugs with the potential to replace or complement established therapies and will receive initial funding by the BioChancePlus program from the German Federal Ministry of Education and Research (BMBF).
Most read news
Organizations
Other news from the department science
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.